BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	Related Studies

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
Information provided by MedImmune LLC

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126646

Locations


United States, Maryland
	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
	Bethesda, Maryland, United States, 20892-1182

Sponsors and Collaborators

MedImmune LLC

Investigators


Principal Investigator:	Robert Kreitman, MD	National Cancer Institute (NCI)